BioInvent/Genentech's cardiovascular drug misses Phase II endpoint
This article was originally published in Scrip
Executive Summary
Despite high hopes for BI-204, a treatment for acute coronary artery disease, BioInvent International has reported that the Phase IIa GLACIER trial investigating the product has failed to meet the primary endpoint.